Skip to main content

Novel medication targets for the treatment of alcoholism: preclinical studies.

Publication ,  Journal Article
Rezvani, AH; Lawrence, AJ; Arolfo, MP; Levin, ED; Overstreet, DH
Published in: Recent Pat CNS Drug Discov
August 2012

Alcoholism is a complex heterogeneous disease and a number of neurotransmitter and neuromodulator systems have been implicated in its manifestation. Consequently, it is unlikely that existing medications such as disulfiram (Antabuse®), naltrexone (ReVia®), acamprosate (Campral®)) can be efficacious in every individual. Thus, the development of novel therapeutic agents with greater selectivity and less unwanted effects for the treatment of this disease is one of the major objectives of alcohol research. This review summarizes the findings of five novel compounds with different neuronal targets for treating alcoholism. These compounds include sazetidine-A, which selectively desensitizes α4β2 nicotinic receptors; carisbamate, a novel anti-epileptic agent; JNJ5234801, a novel anxiolytic agent; GS-455534, a highly selective inhibitor of mitochondrial aldehyde dehydrogenase; and JNJ-39220675, a selective histamine H3 antagonist. Inbred alcohol-preferring rats (iP), Fawn-Hooded (FH) rats, and P rats were used to evaluate the compounds. Naltrexone was used as a positive control in some experiments. All five compounds reduced alcohol consumption and preference. The mechanisms thought to underlie these effects suggest that, in addition to dopaminergic and opioidergic systems, other neuronal systems such as sodium channels (carisbamate), mitochondrial aldehyde dehydrogenase (GS-455534), 5-HT2 receptors (JNJ-5234801), histamine H3 receptors (JNJ-39220675), and α4β2 nicotinic receptors (sazetidine-A) can be involved in alcohol drinking. Further work is necessary to confirm the exact mechanisms of action of each drug and to determine any viable targets for putative treatment of alcohol-use disorders. The article presents some promising patents on novel medication targets for the treatment of alcoholism.

Duke Scholars

Published In

Recent Pat CNS Drug Discov

DOI

EISSN

2212-3954

Publication Date

August 2012

Volume

7

Issue

2

Start / End Page

151 / 162

Location

United Arab Emirates

Related Subject Headings

  • Synaptic Transmission
  • Pyridines
  • Piperidines
  • Patents as Topic
  • Neurology & Neurosurgery
  • Molecular Targeted Therapy
  • Isoflavones
  • Humans
  • Drugs, Investigational
  • Drug Evaluation, Preclinical
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rezvani, A. H., Lawrence, A. J., Arolfo, M. P., Levin, E. D., & Overstreet, D. H. (2012). Novel medication targets for the treatment of alcoholism: preclinical studies. Recent Pat CNS Drug Discov, 7(2), 151–162. https://doi.org/10.2174/157488912800673182
Rezvani, Amir H., Andrew J. Lawrence, Maria P. Arolfo, Edward D. Levin, and David H. Overstreet. “Novel medication targets for the treatment of alcoholism: preclinical studies.Recent Pat CNS Drug Discov 7, no. 2 (August 2012): 151–62. https://doi.org/10.2174/157488912800673182.
Rezvani AH, Lawrence AJ, Arolfo MP, Levin ED, Overstreet DH. Novel medication targets for the treatment of alcoholism: preclinical studies. Recent Pat CNS Drug Discov. 2012 Aug;7(2):151–62.
Rezvani, Amir H., et al. “Novel medication targets for the treatment of alcoholism: preclinical studies.Recent Pat CNS Drug Discov, vol. 7, no. 2, Aug. 2012, pp. 151–62. Pubmed, doi:10.2174/157488912800673182.
Rezvani AH, Lawrence AJ, Arolfo MP, Levin ED, Overstreet DH. Novel medication targets for the treatment of alcoholism: preclinical studies. Recent Pat CNS Drug Discov. 2012 Aug;7(2):151–162.

Published In

Recent Pat CNS Drug Discov

DOI

EISSN

2212-3954

Publication Date

August 2012

Volume

7

Issue

2

Start / End Page

151 / 162

Location

United Arab Emirates

Related Subject Headings

  • Synaptic Transmission
  • Pyridines
  • Piperidines
  • Patents as Topic
  • Neurology & Neurosurgery
  • Molecular Targeted Therapy
  • Isoflavones
  • Humans
  • Drugs, Investigational
  • Drug Evaluation, Preclinical